US 12,167,999 B2
Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
Gregory A. Demopulos, Mercer Island, WA (US); and Vincent A. Florio, Seattle, WA (US)
Assigned to Rayner Intraocular Lenses Limited, Worthing (GB)
Filed by Rayner Intraocular Lenses Limited, Worthing (GB)
Filed on Dec. 17, 2021, as Appl. No. 17/554,842.
Application 17/554,842 is a continuation of application No. 16/276,337, filed on Feb. 14, 2019, granted, now 11,234,965.
Application 16/276,337 is a continuation of application No. 15/836,772, filed on Dec. 8, 2017, abandoned.
Application 15/836,772 is a continuation of application No. 14/953,806, filed on Nov. 30, 2015, abandoned.
Claims priority of provisional application 62/086,133, filed on Dec. 1, 2014.
Prior Publication US 2022/0175727 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/192 (2006.01); A61K 31/405 (2006.01); A61K 31/4174 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/0048 (2013.01); A61K 31/137 (2013.01); A61K 31/192 (2013.01); A61K 31/405 (2013.01); A61K 31/4174 (2013.01)] 7 Claims
 
1. A method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure in a subject identified as having an elevated risk of suffering from a postoperative inflammatory condition because of a preoperative physiologic condition, a preoperative treatment history, surgical trauma, or the surgical placement of a device that is associated with an enhanced incidence of postoperative inflammation, the method comprising: administering intracamerally to the subject during an ophthalmologic surgical procedure an effective amount of a solution including ketorolac and phenylephrine in an intraocular irrigation carrier, wherein the effective amount is the amount of the solution sufficient for uptake of an amount of ketorolac in ocular tissues sufficient for at least 90% inhibition of baseline cyclooxygenase-1 and cyclooxygenase-2 activity levels in ocular tissues for a period of at least six hours postoperatively, wherein the postoperative inflammatory condition is cystoid macular edema or uveitis.